Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Arcellx Inc (ACLX – Research Report), Afya (AFYA – Research Report) and Landos Biopharma (LABP – Research Report).
Arcellx Inc (ACLX)
Bank of America Securities analyst Jason Gerberry reiterated a Buy rating on Arcellx Inc yesterday and set a price target of $57.00. The company’s shares closed last Monday at $45.50, close to its 52-week high of $48.92.
According to TipRanks.com, Gerberry is a 2-star analyst with an average return of
Currently, the analyst consensus on Arcellx Inc is a Strong Buy with an average price target of $51.38, representing a 12.9% upside. In a report issued on October 30, TD Cowen also initiated coverage with a Buy rating on the stock.
See Insiders’ Hot Stocks on TipRanks >>
Afya (AFYA)
In a report released today, Fred Mendes from Bank of America Securities reiterated a Buy rating on Afya, with a price target of $24.00. The company’s shares closed last Monday at $17.60, close to its 52-week high of $17.78.
Mendes has an average return of
According to TipRanks.com, Mendes is ranked #868 out of 8631 analysts.
Afya has an analyst consensus of Strong Buy, with a price target consensus of $22.00.
Landos Biopharma (LABP)
Leerink Partners analyst Thomas Smith maintained a Hold rating on Landos Biopharma on November 9 and set a price target of $5.00. The company’s shares closed last Monday at $3.79.
According to TipRanks.com, Smith is a top 100 analyst with an average return of
Landos Biopharma has an analyst consensus of Hold, with a price target consensus of $5.00, representing a 39.7% upside. In a report issued on November 10, JonesTrading also maintained a Hold rating on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ACLX:
